Condition (MeSH)
Amebiasis
ClinicalTrials.gov lists 30 trials for Amebiasis or a narrower condition beneath it. SIFI SpA has the most among industry and government lead sponsors, with 4.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Trials per phase
9 of the 30 trials are tagged with Amebiasis itself; the rest are tagged with a narrower condition beneath it.
When did Amebiasis trials start? (17)
Shown in this order: most recent first, 1990 onwards. 2026 is partial: trials registered with a 2026 start date so far, not a full year.
Trials over time, by phase
- Phase 1
- Phase 2
- Phase 3
- Phase 4
- Not applicable
- Observational
Top of scale: 4
Trials registered with a start date in each year, 1990 onward, stacked by phase (complete years only; the current partial year is in the table's notes). The table below lists the same counts, most recent years first.
| Year | Trials started |
|---|---|
| 2026 (partial year) | 1 |
| 2025 | 1 |
| 2024 | 4 |
| 2023 | 2 |
| 2022 | 2 |
| 2021 | 1 |
| 2018 | 1 |
| 2017 | 2 |
| 2016 | 2 |
| 2015 | 3 |
Showing 10 of 17 earlier years.
No forecast is made for this condition: it averages 2.0 trial starts a year over the five years to September, under the 5 a year the method needs.
Recruitment duration, a model prediction: 1 trial still running at the 2026-10-09 snapshot, fewer than the 5 needed for a median. Source: ClinicalTrials.gov / AACT (CTTI), public domain.
What phase are Amebiasis trials in? (6)
Shown in this order: phase order.
Show the trials by phase as a table
| Phase | Trials |
|---|---|
| Phase 1 | 2 |
| Phase 2 | 2 |
| Phase 3 | 6 |
| Phase 4 | 2 |
| Not applicable | 2 |
| Observational | 16 |
How many Amebiasis trials are recruiting? (5)
Shown in this order: the order a trial moves through, from not yet recruiting to unknown.
| Status | Trials |
|---|---|
| Not yet recruiting | 1 |
| Recruiting | 1 |
| Completed | 19 |
| Terminated | 1 |
| Unknown status | 8 |
Status as registered on ClinicalTrials.gov. Each trial is counted once.
Which lead sponsors run the most Amebiasis trials? (5)
Shown in this order: most trials first. Lead sponsors the registry classes as industry, NIH, US federal, other government or network. A hospital or university the registry files as government can appear here. Sponsors it classes as academic or other are shown on the full page, because that class cannot separate an institution from a named investigator.
| Sponsor | Trials |
|---|---|
| SIFI SpA | 4 |
| National Institute of Allergy and Infectious Diseases (NIAID) | 3 |
| Pfizer | 2 |
| Romark Laboratories L.C. | 2 |
| Janssen-Cilag Ltd. | 1 |
Which drugs are being tested for Amebiasis? (2)
Shown in this order: most trials first. One row per drug, matched to a single molecule under all its names, ranked by number of trials.
| Drug | Trials |
|---|---|
| Auranofin | 2 |
| Nitazoxanide | 2 |
Interventions as named in the registry (13)
Shown in this order: most trials first.
| Drug | Trials |
|---|---|
| PHMB 0.08% | 2 |
| C: moxifloxacin | 1 |
| 2% chlorhexidine | 1 |
| Propamidine 0.1% | 1 |
| 0.06% PHMB | 1 |
Showing 5 of 13 interventions.
These are the names sponsors entered on ClinicalTrials.gov that we have not matched to a single molecule. Some are drugs under a brand or code name; others are procedures, doses or arm labels.
Which serious adverse events do Amebiasis trials report? (10)
Shown in this order: most subjects affected first. Subjects affected summed across trials, a cross-trial signal, not a rate.
| Adverse event | Subjects affected | Trials |
|---|---|---|
| Therapeutic Penetrating Keratoplasty | 49 | 1 |
| Therapeutic Penetrating Keratoplasty and Corneal Perforation | 13 | 1 |
| Corneal perforation | 4 | 1 |
| Disseminated intravascular coagulation | 2 | 1 |
| Liver disorder | 2 | 1 |
Showing 5 of 10 adverse events.
Which publications cover Amebiasis? (5)
Shown in this order: major-topic papers first, then newest, then most linked to trials.
| Publication | Journal | Year | Major topic |
|---|---|---|---|
| Diagnosing Balamuthia mandrillaris Encephalitis With Metagenomic Deep Sequencing. | Annals of neurology | 2015 | Yes |
| Clinical metagenomic identification of Balamuthia mandrillaris encephalitis and assembly of the draft genome: the continuing case for reference genome sequencing. | Genome medicine | 2015 | Yes |
| Amoebic infection of the eye. | Lancet (London, England) | 1974 | Yes |
| Clinical characteristics of inflammatory bowel disease in Turkey: a multicenter epidemiologic survey. | Journal of clinical gastroenterology | 2009 | No |
| The changing patterns of liver abscess during the past 20 years--a study of 482 cases. | Yonsei medical journal | 1993 | No |
Sub-conditions in MeSH (4)
MeSH descendants one level down with at least one trial, most trials first.
Not on this page
Not measured: delivery record.
Checked, with nothing recorded for this condition: prevalence and rare-disease identity.